Our results show that HF enhances p-eIF2α levels in AML cells, and this activation of p-eIF2α mediates the anti-leukemia activity of HF, underscoring p-eIF2α as a critical mediator of HF activity. The gene discussed is EIF2A; the disease is acute myeloid leukemia.